Parametric Portfolio Associates LLC boosted its holdings in shares of Five Prime Therapeutics Inc (NASDAQ:FPRX) by 227.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 44,855 shares of the biotechnology company’s stock after buying an additional 31,173 shares during the quarter. Parametric Portfolio Associates LLC’s holdings in Five Prime Therapeutics were worth $270,000 at the end of the most recent quarter.
Other institutional investors have also bought and sold shares of the company. Alambic Investment Management L.P. acquired a new position in Five Prime Therapeutics during the second quarter worth $69,000. Bailard Inc. increased its position in Five Prime Therapeutics by 23.8% during the second quarter. Bailard Inc. now owns 13,000 shares of the biotechnology company’s stock worth $78,000 after buying an additional 2,500 shares during the last quarter. Athanor Capital LP acquired a new position in Five Prime Therapeutics during the second quarter worth $104,000. GSA Capital Partners LLP acquired a new position in Five Prime Therapeutics during the second quarter worth $119,000. Finally, Campbell & CO Investment Adviser LLC increased its position in Five Prime Therapeutics by 101.9% during the second quarter. Campbell & CO Investment Adviser LLC now owns 24,066 shares of the biotechnology company’s stock worth $145,000 after buying an additional 12,146 shares during the last quarter. 74.22% of the stock is currently owned by hedge funds and other institutional investors.
FPRX stock opened at $3.99 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.87 and a current ratio of 6.87. Five Prime Therapeutics Inc has a 52-week low of $3.22 and a 52-week high of $14.45. The company has a 50-day moving average of $4.82 and a two-hundred day moving average of $7.21.
Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.99) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.90) by ($0.09). Five Prime Therapeutics had a negative net margin of 842.84% and a negative return on equity of 62.13%. The firm had revenue of $3.33 million for the quarter, compared to the consensus estimate of $5.53 million. Equities analysts anticipate that Five Prime Therapeutics Inc will post -3.91 EPS for the current fiscal year.
In related news, major shareholder Bvf Partners L. P/Il bought 525,070 shares of Five Prime Therapeutics stock in a transaction that occurred on Monday, October 7th. The stock was acquired at an average price of $3.75 per share, for a total transaction of $1,969,012.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Value Fund L. P. Biotechnology bought 601,482 shares of Five Prime Therapeutics stock in a transaction that occurred on Tuesday, October 8th. The stock was bought at an average price of $3.74 per share, with a total value of $2,249,542.68. Insiders have acquired 1,142,552 shares of company stock valued at $4,278,395 over the last 90 days. Corporate insiders own 7.10% of the company’s stock.
Several equities analysts have commented on the stock. ValuEngine raised shares of Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Guggenheim cut shares of Five Prime Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, September 30th. Finally, Zacks Investment Research upgraded shares of Five Prime Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 6th. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company. Five Prime Therapeutics has a consensus rating of “Hold” and an average target price of $14.40.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.
Featured Story: What is Elliott Wave theory?
Want to see what other hedge funds are holding FPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Five Prime Therapeutics Inc (NASDAQ:FPRX).
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.